About Us

Our Company

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Our team has a proven track record of successful drug development and commercialization. Our clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Our late-stage product candidate, belumosudil (KD025), is an orally administered selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2) in development for the treatment of inflammatory and fibrotic diseases. A pivotal study of belumosudil is underway in chronic graft-versus-host disease (cGVHD) as well as a Phase 2 study in systemic sclerosis. Kadmon is also developing next-generation immuno-oncology (I-O) therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. Our lead I-O product candidate, KD033, an anti-PD-L1/IL-15 fusion protein, is being studied in a Phase 1 clinical trial.